Contact
searchSearch
HMP Global
Login

Meeting Materials

Abstracts

PO1
Incidence of leptomeningitis in acute leukemia
Introduction/Background/Significance: Across all cancer diagnoses, leptomeningeal involvement is seen in roughly 5% of patients and carries a poor prognosis with median survival under 3 m...
10/17/2025
PO2
A Case of T-Cell Large Granular Lymphocytic Leukemia in a Patient with Longstanding Rheumatoid Arthritis and Neutropenic Sepsis
Introduction/Background/Significance: T-cell large granular lymphocytic leukemia (T-LGLL) is a rare lymphoproliferative disorder characterized by the clonal expansion of cytotoxic T-cells...
10/17/2025
PO116
Abstract Withdrawn
10/17/2025
PO120
Selinexor-triplet therapy in patients with Central Nervous System Multiple Myeloma: A case series
Introduction/Background/Significance: Multiple myeloma with CNS involvement is a rare but aggressive manifestation of the disease and is highly associated with poor outcome. Disease contr...
10/17/2025
PO4
Clinical outcomes based on molecular risk stratification using next-generation sequencing in adult filipino patients with AML at a tertiary hospital
Introduction/Background/Significance: Acute myeloid leukemia (AML) is a common hematologic malignancy found in adults characterized by a range of genetic abnormalities. Next-generation se...
10/17/2025
PO7
Impact of Sepsis in Acute Myeloid Leukemia Outcomes: A National Inpatient Sample Analysis from 2016 to 2020
Introduction/Background/Significance: While the prognosis of Acute Myeloid Leukemia (AML) has improved with the advent of novel therapies, sepsis remains a leading cause of morbidity and ...
10/17/2025
PO5
A Systematic Review of the Cost-Effectiveness Evaluation of Tisagenlecleucel for the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Pediatric and Young Adult Populations
Introduction/Background/Significance: Relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) presents a major clinical challenge, particularly in pediatric and young adult...
10/17/2025
PO8
Lack of TET2 gene mutation in Tunisian acute myeloid leukemia
Introduction/Background/Significance: Acute myeloid leukemia (AML) is a malignancy associated with altered myeloid lineage precursor hyperplasia and accompanied by different genetic mutat...
10/17/2025
PO6
Impact of Nutritional Status as a Risk Factor for Cardiotoxicity in Children with Leukemia
Introduction/Background/Significance: Acute lymphoblastic leukemia (ALL) is the most common childhood cancer in the world. Doxorubicin (Dox) is a very useful drug in these patients, howev...
10/17/2025
PO9
Addressing Gender Disparities in Professional Visibility: Insights from Social Media Engagement in Hematology Oncology Education
Introduction/Background/Significance: Gender disparities in professional visibility remain a significant barrier to achieving equity in oncology and hematology education. Women represent ...
10/17/2025
PO10
Bridging Information and Action: Opportunities and Equity Challenges in Social Media–Driven Cancer Awareness
Introduction/Background/Significance: Social media is a powerful tool for disseminating cancer prevention and early detection information but faces challenges such as gender disparities, ...
10/17/2025
PO11
Bridging Global Gaps in Immuno-Oncology Education Through a Virtual Education Platform
Introduction/Background/Significance: Social media has emerged as a power outlet for medical information, especially in resource-limited regions. However, one third of social media posts ...
10/17/2025
PO12
Observation as a Treatment Option in DDX41 mutated AML: A Case Report
Introduction/Background/Significance: Mutation of DDX41 (Dead/H-box helicase) gene, located on Chromosome 5q35.3, is seen in 1-2% of MDS/AML cases and demonstrates higher overall survival...
10/17/2025
PO18
Case Report: Presentation and management of extramedullary blast crisis presenting as retroperitoneal hematoma on a newly diagnosed CML patient
Introduction/Background/Significance: Chronic myelogenous leukemia (CML) is a hematopoietic stem cell disorder characterized by the Philadelphia chromosome translocation (BCR-ABL1), leadi...
10/17/2025
PO13
Isolated Neutropenia as a Sentinel of High-Risk Clonal Evolution: A Case of Acute Myeloid Leukemia-Myelodysplasia Related Changes harboring TP53 deletion via Isochromosome 17q and deletion 20q mimicking Myeloproliferative Neoplasm
Introduction/Background/Significance: Isolated neutropenia is often dismissed as benign, particularly in elderly patients where it is typically attributed to age-related marrow changes, m...
10/17/2025
PO20
Exploring the Impact of Race and Comorbidities on AML Hospital Outcomes
Introduction/Background/Significance: American cancer society is estimating 22, 000 new diagnosis of Acute Myeloid Leukemia (AML) and half of that diagnosis will die from AML. AML account...
10/17/2025
PO14
Common Causes and Healthcare Utilization Associated With 90-Day All-Cause Readmissions Following Index Hospitalization for Acute Myeloid Leukemia: An Analysis of the National Readmissions Database
Introduction/Background/Significance: Acute myeloid leukemia accounts for nearly one-third of all leukemia cases and causes over 11,000 deaths annually. Gaps remain in understanding how h...
10/17/2025
PO21
Racial and Epidemiologic Patterns in Hospitalized CML Patients: A Multi-Year National Analysis
Introduction/Background/Significance: According to the American Cancer Society, nearly new cases of chronic myeloid leukemia (CML) are expected to be diagnosed in the United States in 202...
10/17/2025
PO15
A Management Conundrum: Active Infection and Secondary Immune Thrombocytopenia in an Immunocompromised Patient
Introduction/Background/Significance: Immune Thrombocytopenia (ITP) is an acquired autoimmune disorder characterized by platelet count < 100 K/uL. Pathogenesis involves peripheral dest...
10/17/2025
PO22
Impact of pharmacogenetics on the population pharmacokinetics and toxicity of L-asparaginase in children with acute lymphoblastic leukemia
Introduction/Background/Significance: L-asparaginase (L-Asp) remains an essential component in the treatment of pediatric acute lymphoblastic leukemia (ALL). However, its use is often lim...
10/17/2025
PO16
Olutasidenib outcomes by prior number of regimens in the phase 2 pivotal cohort of patients with R/R AML
Introduction/Background/Significance: A subset of patients (7%-14%) with acute myeloid leukemia (AML) have mutations in the isocitrate dehydrogenase 1 gene (mIDH1). Olutasidenib, a select...
10/17/2025
PO24
Effects of imatinib on thyroid function in adult patients with chronic myeloid leukemia
Introduction/Background/Significance: Chronic myeloid leukemia is characterized by the presence of the BCR-ABL1 oncoprotein, against which the tyrosine kinase inhibitor imatinib was devel...
10/17/2025
PO17
From hypereosinophilic syndrome to acute lymphoblastic leukemia: when eosinophilia reveals an occult neoplasia.
Introduction/Background/Significance: Background: Hypereosinophilic syndrome (HES) is defined by persistent eosinophilia ≥1.5×10^9/L, whether associated with eosinophil-mediated organ dam...
10/17/2025
PO28
Mutational analysis of IDH1 gene in acute myeloid leukemia
Introduction/Background/Significance: Isocitrate dehydrogenase (IDH) mutations are considered as key metabolic enzymes that lead to the production of the oncometabolite 2-hydroxyglutarate...
10/17/2025
PO19
Trends in Mortality and Comorbidity Burden in Myelodysplastic Syndrome Patients Across Racial Groups (2016,2019,2022)
Introduction/Background/Significance: Myelodysplastic syndrome (MDS) is characterized by abnormal blood cell production in the bone marrow. Although exact numbers may vary, approximately ...
10/17/2025
PO29
Turmeric/curcumins in diet may enhance blood cancer therapy and reduce treatment related side effects
Introduction/Background/Significance: All trans retinoic acid, RA (tretinoin) is structurally related to vitamin A, is effectively used to treat hematological malignancies including acute...
10/17/2025
PO23
Silent Clonality Essential Thrombocythemia: High-Risk Thrombotic Presentation and the Diagnostic Role of Next-Generation Sequencing
Introduction/Background/Significance: Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by sustained thrombocytosis (platelet count ≥450 × 109/L), excl...
10/17/2025
PO33
Risk of Pulmonary Hypertension in High-Risk Polycythemia Vera: A Retrospective Cohort Study
Introduction/Background/Significance: Polycythemia vera (PV) is a chronic myeloproliferative neoplasm associated with thrombotic complications and progressive end-organ dysfunction. Pulmo...
10/17/2025
PO25
Intracranial Myeloid Sarcoma: An Extremely Unusual Cause of Visual Hallucinations, Memory Loss, Personality Changes, and Depression in an Elderly Woman
Introduction/Background/Significance: Elderly patients often present with vague neuropsychiatric symptoms, posing diagnostic challenges. Myeloid sarcoma (MS) is an uncommon manifestation ...
10/17/2025
PO35
Disparities in Palliative Care Consultations Among Hospitalized Patients with High-Risk Myelodysplastic Syndromes: Analysis of the National Inpatient Sample 2020–2022
Introduction/Background/Significance: Palliative care (PC) improves quality of life and end-of-life outcomes for patients with high-risk myelodysplastic syndromes (MDS), yet utilization p...
10/17/2025
PO26
First Philippine Report of Myeloproliferative Neoplasms with Concurrent JAK2 and BCR::ABL1 Mutations
Introduction/Background/Significance: Myeloproliferative neoplasms (MPNs) are clonal hematologic disorders categorized into BCR::ABL1-positive chronic myeloid leukemia (CML) and BCR::ABL1...
10/17/2025
PO36
Improved 1-Year Survival in AML Patients Aged ‚â•75 After 2018: A SEER-Based Population Study
Introduction/Background/Significance: Older adults with acute myeloid leukemia (AML) historically experience poor outcomes, particularly those aged ≥75. The introduction of venetoclax-bas...
10/17/2025
PO27
Twists and Turns: Unmasking Myeloproliferative Neoplasms Through Surgical Complications of Wandering Spleen
Introduction/Background/Significance: Massive splenomegaly is a hallmark manifestation of advanced myeloproliferative neoplasms (MPNs), particularly primary myelofibrosis (PMF) and chroni...
10/17/2025
PO37
T-cell prolymphocytic leukemia (T-PLL) Mimicking Cardiac Disease: Expanding the Spectrum of Initial Presentation
Introduction/Background/Significance: Background: T-cell prolymphocytic leukemia (T-PLL) is a rare and aggressive mature T-cell leukemia, making up 2% of mature leukemias and characterize...
10/17/2025
PO30
Vertebral fracture as an initial manifestation of Acute Lymphoblastic Leukemia: A case series
Introduction/Background/Significance: The skeletal manifestations of Acute Lymphoblastic Leukemia (ALL) usually present as generalized or local bone pain, or joint pain. There are anecdot...
10/17/2025
PO39
Treatment Outcome & Complications of Patients with Chronic Lymphocytic Leukemia Treated at King Faisal Specialist Hospital & Research Center-Jeddah over a Decade. A single Center Experience in the Kingdom of Saudi Arabia.
Introduction/Background/Significance: Over a decade, there was a significant change in the management of patients with Chroni Lymphocytic Leukemia (CLL) from the diagnostic and therapeuti...
10/17/2025
PO31
Recurrent Gestational Acute Myeloid Leukemia: A case report
Introduction/Background/Significance: Pregnancy induces a unique immunological state characterized by increased tolerance and controlled immune response.Acute Leukemias as usually seen in...
10/17/2025
PO42
Chylothorax as a Rare Complication of Chronic Lymphocytic Leukemia in a Filipino patient
Introduction/Background/Significance: Chronic Lymphocytic Leukemia (CLL), a common adult leukemia in Western population remains exceptionally rare among Asians, particularly Filipinos. Mo...
10/17/2025
PO34
Guillain Barre Syndrome: A rare neuro toxicity following All Trans Retinoic Acid and Arsenic Trioxide induction chemotherapy in a patient with Acute Promyelocytic leukemia
Introduction/Background/Significance: Guillain-Barré syndrome (GBS) is an acute inflammatory demyelinating polyneuropathy usually triggered by infections. Arsenic Trioxide (ATO) and All T...
10/17/2025
PO43
Comparative Cardiotoxicity of BTK Inhibitors in CLL: A Real-World Analysis
Introduction/Background/Significance: The advent of Bruton tyrosine kinase inhibitors has significantly improved outcomes for patients with chronic lymphocytic leukemia (CLL). However, as...
10/17/2025
PO38
One-Year Real-World Outcomes of Venetoclax Versus BTK Inhibitors based regimens in CLL: Insights from a Global, Propensity-Matched EHR Study
Introduction/Background/Significance: The emergence of targeted agents, including BCL2 inhibitor venetoclax and Bruton's tyrosine kinase inhibitors (BTKis), has transformed the management...
10/17/2025
PO51
Exploring GLP-1 Receptor Agonists for Weight Loss in Patients with Hematologic Malignancies: Evidence from a Retrospective Cohort
Introduction/Background/Significance: Obesity and metabolic dysfunction are common in patients with hematological malignancies (such as lymphoma, leukemia, myeloma, myelodysplastic syndro...
10/17/2025
PO40
Unexpected Priapism Secondary to Chronic Myeloid Leukemia in Chronic Phase
Introduction/Background/Significance: Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm driven by the BCR-ABL1 fusion gene with overproduction of granulocytes and typically ...
10/17/2025
PO52
A Phase 1 Study of LP-284 in Adult Patient with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas and Solid Tumors
Introduction/Background/Significance: Background: Treating aggressive relapsed or refractory (R/R) non-hodgkin lymphoma (NHL) can be challenging, especially for those patients progressing...
10/17/2025
PO44
High Resource Utilization and Predictable Complications Drive Readmissions in Chronic Lymphocytic Leukemia: A 2022 Nationwide Readmissions Database Analysis
Introduction/Background/Significance: CLL is one of the most common types of leukemia. With new advances, we’ve seen an increase in survival for patients, yet there's still a lot we can l...
10/17/2025
PO55
Predictors of Severe Neurotoxicity in Patients Receiving Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B-Cell Lymphomas: A Multi-Institutional Real-World Analysis
Introduction/Background/Significance: CD19-directed CAR-T cell therapy has transformed the treatment landscape for relapsed/refractory B-cell lymphomas. Nevertheless, the risk of immune e...
10/17/2025
PO45
High-Risk Chronic Lymphocytic Leukemia in a Young Adult Filipino Female treated with Reduced-dosage, Fixed-duration Ibrutinib and Venetoclax
Introduction/Background/Significance: Chronic lymphocytic leukemia (CLL) is a disease primarily of the elderly, however, in rare cases, it can occur among adolescent and young adults (AYA...
10/17/2025
PO59
Cardiac NK/T-Cell Lymphoma: Largest Case Series and MYC Inhibition–Radiation Synergy as a Potential Bridge to Modified SMILE
Introduction/Background/Significance: Cardiac involvement by extranodal NK/T-cell lymphoma (ENKTL) is exceedingly rare and almost uniformly fatal, largely because diagnosis is delayed and...
10/17/2025
PO46
Chronic Myeloid Leukemia Presenting with Hyperleukocytosis and Coagulopathy, Complicated by Gout and Renal Mass
Introduction/Background/Significance: Hyperleukocytosis (WBC >100,000/μL), typically seen in acute leukemia, can also occur in chronic myeloid leukemia (CML) and is associated with hig...
10/17/2025
PO60
Rare Presentation of Double Expressor Diffuse Large B-Cell Lymphoma with Early CNS Involvement: Successful Multidisciplinary Management
Introduction/Background/Significance: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form of non-Hodgkin lymphoma. A subset known as double-expressor lymphoma (DEL), ...
10/17/2025
PO47
An Unexpected Culprit: Leukemic Pulmonary Infiltration in Early-Stage Chronic Lymphocytic Leukemia
Introduction/Background/Significance Chronic lymphocytic leukemia (CLL) typically follows an indolent course and is often managed expectantly in early stages such as Rai stage 0. Pulmonar...
10/17/2025
PO62
Hodgkin's Lymphoma Presenting With Peripheral Neuropathy
Introduction/Background/Significance: Lymphoma-associated paraneoplastic neuropathy is uncommon, accounting only 6.4% of cases. The central and peripheral nervous systems may be affected,...
10/17/2025
PO48
Bexobrutideg (NX-5948), a novel BTK degrader, demonstrates rapid and durable clinical responses in relapsed/refractory CLL: updated findings from ongoing Phase 1a study
Introduction/Background/Significance: Although BTK inhibitors (BTKi) are effective in chronic lymphocytic leukemia (CLL), the emergence of BTKi resistance mutations and identification of ...
10/17/2025
PO69
Patterns and Predictors of 90-Day Readmission in Hodgkin Lymphoma: A Nationwide Analysis Using the 2022 Nationwide Readmission Database
Introduction/Background/Significance: Hodgkin lymphoma, though rare, continues to carry a high mortality rate. Despite favorable five-year survival rates, there remains a knowledge gap re...
10/17/2025
PO49
Atypical Presentation of Chronic Lymphocytic Leukemia With Pelvic Inflammatory Disease in a Mexican Patient
Introduction/Background/Significance: Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in Western countries, typically affecting older adults and characterized by cl...
10/17/2025
PO74
Tumor Lysis Mimicker: Rasburicase-Induced Methemoglobinemia and Hemolysis in an Undiagnosed G6PD-Deficient Patient with Relapsed DLBCL
Introduction/Background/Significance: Rasburicase is widely used to prevent tumor lysis syndrome (TLS) in high-risk hematologic malignancies. However, in patients with glucose-6-phosphate...
10/17/2025
PO50
Angioimmunoblastic T-cell lymphoma in the setting of EBV and occult hepatitis B co-infection - Double viral trigger?
Introduction/Background/Significance: Methotrexate (MTX), an immunosuppressant used for rheumatoid arthritis (RA) and inflammatory myopathies, predisposes patients to lymphoproliferative ...
10/17/2025
PO75
Age at Diagnosis Drives Molecular Pathology and Prognosis in Diffuse Large B-Cell Lymphoma
Results/Description/Main Outcome Measures: Of the 180 DLBCL driver genes analyzed, 16 were found to mutate at a different frequency by age of diagnosis. These included both well-known onc...
10/17/2025
PO53
Safety of Cyclophosphamide Infusion Time Modification from 60 to 30 Minutes in Selected Chemotherapy Regimens for Lymphoma and Multiple Myeloma
Introduction/Background/Significance: Shortening chemotherapy infusion times is associated with improvements in resource use and patient satisfaction, as well as reductions in nursing wor...
10/17/2025
PO76
Unmasking the Hidden Culprit: Aplastic Crisis Revealing Underlying Large Granular Lymphocytic Leukemia
Introduction/Background/Significance: Large granular lymphocytic (LGL) leukemia is a rare, indolent lymphoproliferative disorder often associated with cytopenias and autoimmune features. ...
10/17/2025
PO54
T-prolymphocytic leukemia. Atypical presentation of a rare disease
Introduction/Background/Significance: T-prolymphocytic leukemia (T-PLL) is a rare mature T-cell neoplasm, accounting for approximately 2% of adult leukemias. It primarily affects older ad...
10/17/2025
PO81
Updated Results from EPCORE NHL-6: Phase 2 Study of Subcutaneous Epcoritamab as Outpatient Treatment for 2L+ Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Introduction/Background/Significance: Currently approved bispecific antibodies for R/R DLBCL require inpatient monitoring. Epcoritamab is a CD3×CD20 bispecific antibody approved for R/R D...
10/17/2025
PO56
Essential role of radiotherapy in NK/T-cell lymphoma: evidence from a single-center in Mexico
Introduction/Background/Significance: NK/T-cell lymphoma is an aggressive and rare subtype of non-Hodgkin lymphoma
10/17/2025
PO83
A Case Series of B-Cell Lymphoma Becoming CD20-Negative Upon Progression: Tissue is Always an Issue
Introduction/Background/Significance: Loss of CD20 expression in B-cell lymphoma is rare but clinically significant, often leading to disease progression and resistance to anti-CD20 based...
10/17/2025
PO57
Fixed-Duration Epcoritamab Monotherapy or Epcoritamab Plus Lenalidomide Leads to High Overall Response Rates in Elderly Patients With Comorbidities and Newly Diagnosed Large B-Cell Lymphoma (LBCL): Results From the Phase 2 EPCORE DLBCL-3 Trial
Introduction/Background/Significance: R-mini-CHOP is commonly used for treatment of elderly, frail patients with newly diagnosed LBCL. However, many patients are not suitable candidates f...
10/17/2025
PO84
Symptom Burden and Advanced Stage Predict Delayed Presentation in Non-Hodgkin Lymphoma: A Nigerian Cohort Study
Introduction/Background/Significance: Delayed presentation in lymphoma patients worsens outcomes, particularly in resource-limited settings like Nigeria. This study examines factors assoc...
10/17/2025
PO58
Comparison of Intensive and Less Intensive Chemotherapy on Cognitive Impairment in Survivors of Hodgkin Lymphoma
Introduction/Background/Significance: Cognitive impairment related to cancer or chemotherapy (CRCI) is frequently reported in Hodgkin lymphoma (HL) patients, but the influence of treatmen...
10/17/2025
PO85
Anaplastic Large Cell Lymphoma (ALK-negative) Following Diffuse Large B-Cell Lymphoma: A Rare Sequential Occurrence
Introduction/Background/Significance: Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, typically managed with R-CHOP chemotherapy. While transformation withi...
10/17/2025
PO61
Hepatic Methotrexate-Associated Lymphoproliferative Disorder Complicated by Hemophagocytic Lymphohistiocytosis in a Patient with Inflammatory Myositis: A Case Report
Introduction/Background/Significance: Methotrexate (MTX), an immunosuppressant used for rheumatoid arthritis (RA) and inflammatory myopathies, predisposes patients to lymphoproliferative ...
10/17/2025
PO86
Hi-C FFPE Sequencing for Detection of Fusions and Rearrangements that are Diagnostic, Prognostic, and Therapeutic Biomarkers in Lymphoma
Introduction/Background/Significance: Lymphoma diagnosis relies on histologic examination, immuno-profiling, and often fluorescence in situ hybridization (FISH). Because FISH is perf...
10/17/2025
PO63
Bexobrutideg (NX-5948), a novel BTK degrader, shows high clinical activity and tolerable safety in an ongoing Phase 1a/b study in Waldenström macroglobulinemia
Introduction/Background/Significance: The B-cell receptor signaling pathway mediated by BTK is a validated therapeutic target in Waldenström macroglobulinemia (WM). Bexobrutideg is a nov...
10/17/2025
PO93
SARS-CoV-2, EBV Reactivation, and Lymphomagenesis: A Systematic Review, Meta-Analysis, and Bayesian Modeling
Introduction/Background/Significance: Viruses have long been implicated in human oncogenesis, with Epstein–Barr virus (EBV) serving as a prototype of latent viral persistence capable of d...
10/17/2025
PO64
Transdifferentiation of high-grade B-cell lymphoma into monocytic/histiocytic neoplasm following CD19 CAR-T Therapy: A Case Report
Introduction/Background/Significance: Follicular lymphoma (FL) is classically indolent but may transform into aggressive disease such as high-grade B-cell lymphoma with MYC and BCL2 rearr...
10/17/2025
PO101
Efficacy of Elranatamab (ELRA) in Combination with Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase lb MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)
Introduction/Background/Significance: Elranatamab induced deep and durable responses with manageable safety in BCMA-naive patients with RRMM in MagnetisMM-3 (NCT04649359). Combining elran...
10/17/2025
PO65
A Case of Splenic Marginal Zone Lymphoma Presenting with Hypercalcemia
Introduction/Background/Significance: Splenic marginal zone lymphoma (SMZL) is a rare subtype of non-Hodgkin lymphoma (NHL), representing < 1% of all NHLs. The annual incidence is appr...
10/17/2025
PO102
Outcomes of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis
Introduction/Background/Significance: Ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy that has shown promising efficacy in patients...
10/17/2025
PO66
The Phase 3 waveLINE-010 Study Evaluating Zilovertamab Vedotin Plus R-CHP Versus R-CHOP in Participants With Untreated Diffuse Large B-Cell Lymphoma
Introduction/Background/Significance: The first-line standard-of-care for diffuse large B-cell lymphoma (DLBCL) is rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednison...
10/17/2025
PO106
Retrospective analysis of treatment outcome and complications of patients with Multiple myeloma among patients treated at KFSHRC Jeddah in the period 2011 to 2024, A single center experience.
Introduction/Background/Significance: Multiple Myeloma (MM) is a Hematological malignancy of B-cell plasma cell that affects elderly population. It is the second most common malignancy af...
10/17/2025
PO107
Discordant Biochemical and Clinical Response During Talquetamab Therapy in Multi-Refractory Myeloma
Introduction/Background/Significance: Patients with relapsed/refractory multiple myeloma (RRMM) often undergo numerous lines of therapy, including novel bispecific agents such as talqueta...
10/17/2025
PO67
Epcoritamab Monotherapy Demonstrates Deep and Durable Responses in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): 3-Year Follow-Up From EPCORE NHL-1 and EPCORE NHL-3
Introduction/Background/Significance: Epcoritamab is a subcutaneous CD3xCD20 bispecific antibody approved for R/R FL after ≥2 prior lines of therapy (pLOT; 3L+) based on the phase 1/2 tri...
10/17/2025
PO117
The Impact of Bridging Agents on Costs Associated with CAR T Therapy for Patients with Relapse/Refractory Multiple Myeloma: Results of a Micro-costing Analysis
Introduction/Background/Significance: CAR T therapy is a treatment option for patients with relapse/refractory multiple myeloma (RRMM), however optimizing treatment outcomes may depend on...
10/17/2025
PO68
Asciminib induced Pancreatitis in Chronic Myeloid Leukemia: A Case Report and Literature Review
Introduction/Background/Significance: Asciminib, a BCR-ABL1 tyrosine kinase inhibitor (TKI) that specifically targets the ABL myristoyl pocket, serves as a therapeutic option for patients...
10/17/2025
PO122
Real-World Comparative Outcomes of Anti-CD38 Monoclonal Antibody Retreatment Versus Selinexor-Based Triplets in Relapsed/Refractory Multiple Myeloma (RRMM)
Introduction/Background/Significance: Monoclonal antibodies targeting CD38 (α-CD38), in combination with agents like bortezomib, carfilzomib, and lenalidomide, are a standard therapy for ...
10/17/2025
PO70
MK-3475A in Relapsed or Refractory Classic Hodgkin Lymphoma or Primary Mediastinal Large B-cell Lymphoma: The Single-arm, Open-label Phase 2 MK-3475A-F65 Study
Introduction/Background/Significance: The programmed cell death protein 1 (PD-1) inhibitor pembrolizumab is a standard-of-care treatment option for multiple cancers, including relapsed or...
10/17/2025
PO124
Obese Patients with Multiple Myeloma: A National Retrospective Trend Analysis from 2015 to 2022
Introduction/Background/Significance: Despite global decreases in overall cancer incidence, the incidence of multiple myeloma (MM) continues to increase at both national and global levels...
10/17/2025
PO71
Nemtabrutinib in Relapsed Or Refractory Marginal Zone Lymphoma: Updated Efficacy and Safety From Cohort F of the Phase 2 BELLWAVE-003 Study
Introduction/Background/Significance: Nemtabrutinib, a potent, noncovalent, reversible Bruton tyrosine kinase inhibitor (BTKi) taken by mouth (PO) once daily (QD), has shown promising ant...
10/17/2025
PO125
Outcomes in Smokers with Multiple Myeloma: A National Retrospective Trend Analysis from 2015 to 2022
Introduction/Background/Significance: Despite global decreases in overall cancer incidence, the incidence of multiple myeloma (MM) continues to increase at both national and global levels...
10/17/2025
PO72
Updated Analysis of Cohort G From the Phase 2 BELLWAVE-003 Study Evaluating Nemtabrutinib in Relapsed or Refractory Follicular Lymphoma
Introduction/Background/Significance: Nemtabrutinib, a potent, noncovalent, reversible Bruton tyrosine kinase inhibitor (BTKi) taken by mouth (PO) once daily (QD), has shown encouraging a...
10/17/2025
PO126
Beyond the Bone: When Multiple Myeloma Takes an Unexpected Turn
Introduction/Background/Significance: Multiple myeloma (MM) is a malignant plasma cell disorder that primarily affects the bone marrow, leading to hematologic complications, bone destruct...
10/17/2025
PO73
Long-Term Outcomes in Patients With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Complete Response (CR) at 2‚ÄâYears With Epcoritamab Monotherapy: Novel Analysis of 3-Year Results From the Pivotal EPCORE NHL-1 Trial
Introduction/Background/Significance: In LBCL, duration of CR (DOCR) correlates with long-term outcomes. Epcoritamab, a subcutaneous CD3xCD20 bispecific antibody, is approved for patients...
10/17/2025
PO128
Racial Disparities in Myeloma Incidence, Mortality, and Survival Rates Among Adolescents and Young Adults in the United States: An Analysis of the SEER Database
Introduction/Background/Significance: Background: Adolescent and young adult (AYA) patients between the ages of 15 and 39 form a distinct and under-researched group in oncology. Myeloma i...
10/17/2025
PO77
Brentuximab vedotin as bridging and maintenance therapy in hematopoietic cell transplant in a national access program for relapsed or refractory classical Hodgkin lymphoma patients
Introduction/Background/Significance: Hematopoietic cell transplantation (HCT) is essential for eligible patients with relapsed/refractory classical Hodgkin lymphoma (R/RcHL), but optimal...
10/17/2025
PO129
A Rare Case of Waldenström Macroglobulinemia Presenting with Gastrointestinal Bleeding
Introduction/Background/Significance: Waldenström Macroglobulinemia (WM) is a rare, indolent B-cell lymphoma characterized by the production of monoclonal IgM antibodies. While typical s...
10/17/2025
PO78
Heart and Lymph Nodes: A Love Story Gone Wrong
Introduction/Background/Significance: Hodgkin's lymphoma (HL) is a hematologic malignancy characterized by the presence of Reed-Sternberg cells and commonly presents with lymphadenopathy,...
10/17/2025
PO134
An Approach to Identify a Biomarker for the Development of Secondary Plasma Cell Leukemia
Introduction/Background/Significance: Plasma cell leukemia (PCL) is defined as >2 × 109/liter plasma cells (PCs) in peripheral blood or by >20% in differential leukocyte count. Seco...
10/17/2025
PO79
A case of primary small lymphocytic lymphoma of breast
Introduction/Background/Significance: Non-Hodgkin lymphoma (NHL) can be either indolent or aggressive. Breast involvement by NHL, either primary or secondary is rare, with an incidence of...
10/17/2025
PO135
Quality Improvement Intervention, the addition of Lifestyle Medicine group sessions in Multiple Myeloma population
Introduction/Background/Significance: Multidisciplinary lifestyle medicine education for patients with multiple myeloma is limited despite lifestyle evidence-based recommendations for can...
10/17/2025
PO80
Hodgkin Lymphoma in HIV-Positive Patients: Prognostic Factors and Treatment Strategies
Introduction/Background/Significance: A 42-year-old male presented with malaise, fatigue, generalized lymphadenopathy, and splenomegaly. Lymph node biopsy confirmed a diagnosis of Hodgkin...
10/17/2025
PO139
Real-world Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases
Introduction/Background/Significance: Ciltacabtagene autoleucel (cilta-cel) is a BCMA-directed CAR-T cell therapy approved in the US for relapsed/refractory multiple myeloma (RRMM) as ear...
10/17/2025
PO82
A Challenging Crosstalk between HLH and TCRHLCL
Introduction: Hemophagocytic lymphohistiocytosis (HLH) is a rare, potentially fatal condition characterized by immune hyperactivation. Malignancies (like lymphomas), autoimmune diseases, ...
10/17/2025
PO32
Retrospective Analysis of Treatment Outcome Over 15 Years of Patients with Chronic Myelogenous Leukemia at King Faisal Specialist Hospital - Jeddah
Introduction/Background/Significance: CML is a MPN characterized by the presence of the Philadelphia chromosome t(9;22),. Most patients are diagnosed in chronic phase. Introduction of TKI...
10/21/2025
PO87
Synchronous Central Nervous System and Systemic Involvement in CD30-Positive Diffuse Large B Cell Lymphoma: A Rare Presentation Treated with Alternating R-CHOP plus HD-MTX and R-HIDAC plus HD-MTX
Introduction/Background/Significance: Diffuse large B-cell lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin lymphoma, accounting for 30–40% of cases. It is an aggressive mali...
10/17/2025
PO35
Disparities in Palliative Care Consultations Among Hospitalized Patients with High-Risk Myelodysplastic Syndromes: Analysis of the National Inpatient Sample 2020–2022
Introduction/Background/Significance: Palliative care (PC) improves quality of life and end-of-life outcomes for patients with high-risk myelodysplastic syndromes (MDS), yet utilization p...
02/02/2026
PO89
Primary Pancreatic Follicular Lymphoma: An Elusive Diagnosis Behind a Pancreatic Mass
Introduction/Background/Significance: Primary pancreatic follicular lymphoma (PPFL) is an extremely rare subtype of extranodal follicular lymphoma, accounting for 0.1%-0.5% of malignant l...
10/17/2025
PO59
Cardiac NK/T-Cell Lymphoma: Largest Case Series and MYC Inhibition–Radiation Synergy as a Potential Bridge to Modified SMILE
Introduction/Background/Significance: Cardiac involvement by extranodal NK/T-cell lymphoma (ENKTL) is exceedingly rare and almost uniformly fatal, largely because diagnosis is delayed and...
02/02/2026
PO90
Gray Zone Lymphoma Masquerading as Autoimmune Hepatitis
Introduction/Background/Significance: Gray Zone Lymphoma (GZL), "B-cell lymphoma, unclassifiable, with features intermediate between Diffuse large B cell Lymphoma and classical Hodgkin ly...
10/17/2025
PO129
A Rare Case of Waldenström Macroglobulinemia Presenting with Gastrointestinal Bleeding
Introduction/Background/Significance: Waldenström Macroglobulinemia (WM) is a rare, indolent B-cell lymphoma characterized by the production of monoclonal IgM antibodies. While typical sy...
02/02/2026
PO91
Concurrent Diagnosis of Follicular Lymphoma and High Grade Pancreatic Neuroendocrine Carcinoma: A Rare Dual Malignancy.
Introduction/Background/Significance: The simultaneous diagnosis of two distinct primary malignancies, known as synchronous malignancies, is rare but increasingly recognized, with reporte...
10/17/2025
PO92
Comparative Real-World Outcomes of CAR-T Therapy in Elderly (‚â•70‚ÄâYears) Versus Younger ( <‚Äâ70‚ÄâYears) Patients with Diffuse Large B-Cell Lymphoma
Introduction/Background/Significance: Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized management for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), but rea...
10/17/2025
PO94
A Rare Case of Cutaneous T-Cell Lymphoma With Central Nervous System Involvement: Navigating Diagnostic Uncertainty
Introduction/Background/Significance: Cutaneous T-cell lymphoma (CTCL) is a rare non-Hodgkin lymphoma with an incidence of approximately 8.5 cases per million individuals. Central nervous...
10/17/2025
PO95
A Data-Driven Approach to Guide Representative Clinical Trial Enrollment and Retention Among Patients With Follicular Lymphoma and Marginal Zone Lymphoma.
Background:
10/17/2025
PO96
A Case of Anaplastic Large Cell Lymphoma (ALCL) after Immune Check Point Inhibitor (ICI) Therapy
Introduction/Background/Significance: Therapeutic PD-1/PDL-1 (Programmed Death Ligand) inhibition is associated with hyper-progression of certain T-cell malignancies. PD-1 receptor is a k...
10/17/2025
PO97
Safety Profile of Lisocabtagene Maraleucel in Relapsed or Refractory Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis of Clinical and Real-World Data
Introduction/Background/Significance: Chimeric antigen receptor (CAR) T-cell therapies have transformed the landscape of treatment for relapsed or refractory (R/R) large B-cell lymphoma (...
10/17/2025
PO98
Hemophagocytic Lymphohistiocytosis: Unveil the Mystery
Introduction/Background/Significance: Hemophagocytic Lymphohistiocytosis (HLH) can be primary (Genetic) or Secondary (Acquired). Secondary causes of HLH include infections, malignancy, au...
10/17/2025
PO99
Prevalence and Epidemiology of Light Chain Amyloidosis in Hospitalized Multiple Myeloma Patients
Introduction/Background/Significance: Light chain (AL) amyloidosis is a relatively uncommon but clinically significant complication of multiple myeloma with important prognostic and manag...
10/17/2025
PO100
ALTITUDE-1: Real-world Treatment Patterns Associated with elranatamab Among Patients with Multiple Myeloma
Introduction/Background/Significance: Elranatamab (ELRA) is a humanized bispecific antibody that targets both B-cell maturation antigen (BCMA)-expressing multiple myeloma (MM) cells and C...
10/17/2025
PO103
Unveiling the Real-World Balance of Efficacy and Toxicity: CAR-T versus Bispecific Antibodies for Elderly Patients with Multiple Myeloma
Materials and Methods/Case Presentation/Objective: We performed a retrospective cohort analysis using the TriNetX Network. Patients aged ≥70 years with RRMM treated with either CAR-T (n=3...
10/17/2025
PO104
Antibiotic Exposure Affecting Bortezomib Efficacy in Multiple Myeloma: A Systematic Review
Introduction/Background/Significance: Bortezomib, a proteasome inhibitor, has significantly improved survival outcomes in multiple myeloma (MM). However, resistance remains a major barrie...
10/17/2025
PO105
Comparative Real-World Outcomes of Belantamab Mafodotin Versus Pomalidomide-Based Regimens in Relapsed/Refractory Multiple Myeloma: A Propensity-Matched Cohort Analysis
Introduction/Background/Significance: The therapeutic landscape for relapsed/refractory multiple myeloma (RRMM) continues to evolve with the introduction of novel agents such as belantama...
10/17/2025
PO108
Hyperviscosity Syndrome from IgA Multiple Myeloma: A Rare Diagnosis Revealed by Head Trauma
Introduction/Background/Significance: Multiple myeloma is a clonal plasma cell proliferative disorder in which excess production of monoclonal immunoglobulins by plasma cells leads to end...
10/17/2025
PO109
Delayed Evolution: A Rare Case of Multiple Myeloma Emerging Two Decades After Initial Diagnosis of Amyloidosis
Introduction/Background/Significance: Primary light chain (AL) amyloidosis and multiple myeloma (MM) are both clonal plasma cell disorders. AL amyloidosis and MM are distinguished primari...
10/17/2025
PO110
From Bedbound to Ambulatory: Reversing Disability in Patients with Multiple Myeloma Through Early and Aggressive Intervention
Introduction/Background/Significance: Multiple myeloma (MM) frequently manifests with severe bone involvement, including vertebral pathological fractures and mechanical instability, leadi...
10/17/2025
PO111
Efficacy and safety of elranatamab (ELRA) in patients with relapsed or refractory multiple myeloma (RRMM): a US subgroup analysis from MagnetisMM-3
Introduction/Background/Significance: The ongoing phase 2 MagnetisMM-3 (NCT04649359) study demonstrated the efficacy and safety of ELRA in patients (pts) with RRMM and no prior BCMA-direc...
10/17/2025
PO112
Elranatamab in combination with daratumumab and lenalidomide (EDR) in patients with newly diagnosed multiple myeloma (NDMM) not eligible for transplant: Initial results from MagnetisMM-6 part 1
Introduction/Background/Significance: Elranatamab (ELRA), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, induced deep and durable responses with a manageable safety profile i...
10/17/2025
PO113
IgM Multiple Myeloma in Afro-Caribbean Patients: A Report of Two Cases
Introduction/Background/Significance: IgM multiple myeloma (MM) is a rare plasma cell malignancy representing less than 0.5% of all MM cases. It presents a unique diagnostic challenge due...
10/17/2025
PO114
Pre- and Post-Implementation Evaluation of a Systematized Order Set for Inpatient Hypercalcemia Management
Introduction/Background/Significance: At Mount Sinai Health System (MSHS), hypercalcemia is defined as a corrected serum calcium (CSC) level of at least 10.5 mg/dL or an ionized calcium l...
10/17/2025
PO118
Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Patients With Newly Diagnosed Multiple Myeloma: Subgroup Analysis of Transplant-ineligible Patients in the Phase 3 CEPHEUS Study
Introduction/Background/Significance: D-VRd is the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). In CEPHEUS (NCT03652064), D-VRd improved...
10/17/2025
PO119
Safety and Efficacy of Plerixafor when Administered in Outpatient Clinic or Self-Administered at Home
Introduction/Background/Significance: For patients with Non-Hodgkin lymphoma (NHL) and multiple myeloma (MM) who require an autologous stem cell transplant (ASCT), there are several strat...
10/17/2025
PO121
A Marrowing Tale: A Case of Multiple Myeloma Refractory to Multiple Lines of Treatment
Introduction/Background/Significance: Multiple myeloma (MM) remains primarily a disease of the elderly, with a median age of 66 at presentation. Though the development of newer therapeuti...
10/17/2025
PO123
Secondary Extramedullary Plasmacytoma of the Stomach: A Rare Manifestation of Relapsed Multiple Myeloma
Introduction/Background/Significance: Plasma cell tumors include solitary plasmacytomas and multiple myeloma (MM). Extramedullary plasmacytomas (EMP) are rare soft tissue manifestations o...
10/17/2025
PO127
Isoniazid: A Potential Culprit in Delayed Engraftment
Introduction/Background/Significance: Autologous stem cell transplant (ASCT) is essential in Multiple Myeloma to increase progression free survival. After graft infusion, Neutrophil engra...
10/17/2025
PO130
Predictors of 90-Day All-Cause Readmissions in Multiple Myeloma: Insights From the National Readmissions Database
Introduction/Background/Significance: Multiple myeloma carries a high disease burden, with only a 62% survival rate at the five-year mark. However, little is known about the factors that ...
10/17/2025
PO131
A Rare Case of Extramedullary Plasmacytoma Presenting With Critical Airway Compromise
Introduction/Background/Significance: Plasmacytoma is a rare malignancy of monoclonal plasma cells, with tracheal involvement being exceptionally uncommon. Its indolent course can delay d...
10/17/2025
PO132
Characterization of Ophthalmic Examination Findings (OEF) and Impact on Reading and Driving in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Belantamab Mafodotin (Belamaf)
Introduction/Background/Significance: In the phase 3, randomized DREAMM-7 and DREAMM-8 trials, belamaf plus standard backbone therapies demonstrated significant progression-free survival ...
10/17/2025
PO133
Lost in Translation: The Critical Need for CRS Awareness in Talquetamab Therapy
Introduction/Background/Significance: Multiple Myeloma (MM) is an abnormal growth of plasma cells in the bone marrow and remains a major contributor to mortality. The current treatments f...
10/17/2025
PO136
Optimizing Multiple Myeloma Assessment for Newly Diagnosed Patients at Intermountain Health: A Mixed Methods Analysis
Introduction/Background/Significance: Only 20-50% of eligible patients with multiple myeloma (MM) undergo autologous stem cell transplantation (ASCT). Community oncologists commonly refer...
10/17/2025
PO137
Stem Cell Mobilization using G-CSF plus Plerixafor in multiple myeloma- A Single Center Five Years
Introduction/Background/Significance: Plerixafor is an inhibitor molecule with ability for reversible binding to CXCR-4 receptor – followed by superior stem cell (SC) release/mobilization...
10/17/2025
PO138
A Case of Multiple Myeloma Complicated by Type I Cryoglobulinemia
Introduction/Background/Significance: Type I cryoglobulinemia develops in the setting of monoclonal gammopathies for about 10-15% of cases. Clinically patient's will present with severe c...
10/17/2025
PO140
Employing Chimeric Antigen Receptor (CAR) T-cell Therapy in a Case of Relapsed Multiple Myeloma with Dialysis-Dependent End Stage Renal Disease
Introduction/Background/Significance: Few studies have assessed the outcomes of CAR T-cell therapy in patients with end-stage renal disease (ESRD). Data remain especially limited in the c...
10/17/2025
PO141
High-Grade T-cell Lymphoma Complicating B-cell CLL: An Unusual Manifestation of Richter Transformation
Introduction/Background/Significance: Richter transformation (RT) typically involves transformation of chronic lymphocytic leukemia (CLL) into aggressive B-cell lymphoma. The transformati...
10/17/2025
PO63
Bexobrutideg (NX-5948), a novel BTK degrader, shows high clinical activity and tolerable safety in an ongoing Phase 1a/b study in Waldenström macroglobulinemia
Introduction/Background/Significance: The B-cell receptor signaling pathway mediated by BTK is a validated therapeutic target in Waldenström macroglobulinemia (WM). Bexobrutideg is a nove...
02/02/2026
PO73
Long-Term Outcomes in Patients With Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) and Complete Response (CR) at 2 Years With Epcoritamab Monotherapy: Novel Analysis of 3-Year Results From the Pivotal EPCORE NHL-1 Trial
Introduction/Background/Significance: In LBCL, duration of CR (DOCR) correlates with long-term outcomes. Epcoritamab, a subcutaneous CD3xCD20 bispecific antibody, is approved for patients...
02/02/2026
PO92
Comparative Real-World Outcomes of CAR-T Therapy in Elderly (≥70 Years) Versus Younger ( < 70 Years) Patients with Diffuse Large B-Cell Lymphoma
Introduction/Background/Significance: Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized management for relapsed/refractory diffuse large B-cell lymphoma (DLBCL), but rea...
02/02/2026

About

For nearly 2 decades, the Lymphoma, Leukemia & Myeloma Congress (formerly the Lymphoma & Myeloma Congress) has been recognized around the world as the most respected forum for industry-leading hematologic research.

It’s where interdisciplinary specialists convene to explore the controversial and the complex, the emerging and the exciting, and discuss, debate, and discover along the way.

This program features 4 days of comprehensive learning as we analyze emerging data, discover innovative treatment methods, and get a glimpse into the future of lymphoma, myeloma, and leukemia disorders.

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use